



Near-Perfect Hep C Cure Rate for Glecaprevir/Pibrentasvir in Genotype 2s

AbbVie's investigational daily, fixed-dose combination tablet performed very well among those with milder liver damage.

November 18, 2016

Twelve weeks of AbbVie's investigational daily, fixed-dose combination tablet glecaprevir/pibrentasvir, known as G/P, cured almost all people with genotype 2 of hepatitis C virus (HCV) in a recent trial, aidsmap reports.

Researchers from the Phase III ENDURANCE-2 trial of 302 people with genotype 2 of hep C presented findings at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

The participants included both those who had and had not been treated for hep C before. Seventy-six percent had no fibrosis or mild fibrosis, while 9 percent had moderate fibrosis and 15 percent had advanced fibrosis. None had cirrhosis.

The study members were randomized to receive G/P daily for 12 weeks or a placebo. Then those who had been given the placebo next received 12 weeks of G/P, on an open-label basis, meaning they knew they were taking the active treatment.

Ninety-nine percent of the participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).

The most common adverse health events were headache (12 percent) and fatigue (11 percent). The researchers judged that no serious adverse health events that the participants experienced were related to G/P.

To read the aidsmap article, [click here](#).
